A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors

Geoffrey Y. Ku, Samuel J. Klempner, Farshid Dayyani et al.|Clinical Cancer Research|2025

Cited by 16